Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Odaily Noon Briefing

Odaily Noon Briefing

Odaily星球日报Odaily星球日报2026/05/25 05:32
Show original

1. The US and Iran have reached an agreement on fully opening the Strait of Hormuz;

2. Loracle is facing an unrealized loss of over 30 million US dollars, holding a position of 141 million US dollars and newly opening a 3x VVV short;

3. US Secretary of State: The US and Iran have “reliable plans” for opening the strait and the Iran nuclear issue;

4. Data: StabIR's EURR and USDR suffered losses of over 10 million US dollars after being attacked, and over 100 thousand US dollars of stolen funds have been frozen;

5. StablR: Security vulnerabilities have been identified and are being addressed actively; details and follow-up measures will be announced as soon as possible;

6. A certain whale unstaked 443,200 HYPE and sold 232,000;

7. Bitcoin spot ETF saw a net outflow of 1.257 billion US dollars last week, with BlackRock IBIT having the largest net outflow of 1.008 billion US dollars;

8. Ethereum spot ETF saw a net outflow of 216 million US dollars last week, with BlackRock ETHA having the largest net outflow of 189 million US dollars.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Chinese 3D vision AI startup Sensing4D AI submits IPO application to US stock market: plans to raise $35 million and advance embodied intelligence simulation.

Sensing4D AI plans to go public on Nasdaq, aiming to raise $35 million, with a primary focus on 3D reconstruction and embodied intelligence simulation. The company's annual revenue is $29 million.

智通财经•2026/10/23 08:57

Rezera (RZRA.US) submits IPO application: Oral NLRP3 inhibitor pipeline progresses, Phase 3 PAD trial scheduled to begin in 2027

Rezera plans to go public on Nasdaq to raise 100 millions USD. Its oral NLRP3 inhibitor will initiate a Phase III trial for PAD, with data expected in 2028.

智通财经•2026/10/23 08:32